PTGS2 and Hand-foot syndrome: Among participants of the D-TORCH study, delta serum COX-2 levels were not significantly different by treatment arms or occurrence of HFS, highlighting the need to study tissue expression of COX-2 as a biomarker for capecitabine-induced HFS.